These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35727480)

  • 1. ATP, an attractive target for the treatment of refractory chronic cough.
    Zhang M; Sykes DL; Sadofsky LR; Morice AH
    Purinergic Signal; 2022 Sep; 18(3):289-305. PubMed ID: 35727480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough.
    Dicpinigaitis PV; McGarvey LP; Canning BJ
    Lung; 2020 Aug; 198(4):609-616. PubMed ID: 32661659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
    Muccino D; Green S
    Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
    Garceau D; Chauret N
    Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough.
    Mazzone SB; McGarvey L
    Clin Pharmacol Ther; 2021 Mar; 109(3):619-636. PubMed ID: 32748976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
    Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
    Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapeutic Options for Chronic Refractory Cough.
    Song WJ; Chung KF
    Expert Opin Pharmacother; 2020 Aug; 21(11):1345-1358. PubMed ID: 32301356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.
    Abdulqawi R; Dockry R; Holt K; Layton G; McCarthy BG; Ford AP; Smith JA
    Lancet; 2015 Mar; 385(9974):1198-205. PubMed ID: 25467586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.
    Friedrich C; Francke K; Gashaw I; Scheerans C; Klein S; Fels L; Smith JA; Hummel T; Morice A
    Clin Pharmacokinet; 2022 Aug; 61(8):1143-1156. PubMed ID: 35624408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of gefapixant, a P2X
    McGarvey LP; Birring SS; Morice AH; Dicpinigaitis PV; Pavord ID; Schelfhout J; Nguyen AM; Li Q; Tzontcheva A; Iskold B; Green SA; Rosa C; Muccino DR; Smith JA;
    Lancet; 2022 Mar; 399(10328):909-923. PubMed ID: 35248186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
    Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical perspective - cough: an unmet need.
    Dicpinigaitis PV
    Curr Opin Pharmacol; 2015 Jun; 22():24-8. PubMed ID: 25771118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised trial of the P2X
    Niimi A; Saito J; Kamei T; Shinkai M; Ishihara H; Machida M; Miyazaki S
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34649978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Looking ahead to novel therapies for chronic cough. Part 1 - peripheral sensory nerve targeted treatments.
    Grabczak EM; Dabrowska M; Birring SS; Krenke R
    Expert Rev Respir Med; 2020 Dec; 14(12):1217-1233. PubMed ID: 32804594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough.
    McGarvey L; Sher M; Shvarts YG; Lu S; Wu WC; Xu P; Schelfhout J; La Rosa C; Nguyen AM; Reyfman PA; Afzal AS
    Lung; 2023 Apr; 201(2):111-118. PubMed ID: 36879087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study.
    Zhang M; Morice AH; Si F; Zhang L; Chen Q; Wang S; Zhu Y; Xu X; Yu L; Qiu Z
    Ther Adv Respir Dis; 2023; 17():17534666231167716. PubMed ID: 37078383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.
    Nussbaum JC; Hussain A; Min KC; Marbury TC; Lasseter K; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2022 Nov; 62(11):1435-1444. PubMed ID: 35656754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update and systematic review on drug therapies for the treatment of refractory chronic cough.
    Ryan NM; Vertigan AE; Birring SS
    Expert Opin Pharmacother; 2018 May; 19(7):687-711. PubMed ID: 29658795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of ATP in cough hypersensitivity syndrome: new targets for treatment.
    Zhang M; Wang S; Yu L; Xu X; Qiu Z
    J Thorac Dis; 2020 May; 12(5):2781-2790. PubMed ID: 32642186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic cough: P2X3 receptor antagonists and beyond.
    Sykes DL; Zhang M; Morice AH
    Pharmacol Ther; 2022 Sep; 237():108166. PubMed ID: 35263649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.